PD L1 News and Research

RSS
New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

Regulation of cytotoxic T-cell differentiation and exhaustion by mTOR signaling

Regulation of cytotoxic T-cell differentiation and exhaustion by mTOR signaling

Immunotherapy combination extends progression-free survival in patients with melanoma

Immunotherapy combination extends progression-free survival in patients with melanoma

Molecular insights: Detecting gene fusions offers new avenues for advanced cancer management

Molecular insights: Detecting gene fusions offers new avenues for advanced cancer management

Multifunctional Ga-based nanoparticles combine cancer phototherapy with immunotherapy

Multifunctional Ga-based nanoparticles combine cancer phototherapy with immunotherapy

Nutrition meets cancer therapy: How gut microbiome and diet impact immunotherapy success

Nutrition meets cancer therapy: How gut microbiome and diet impact immunotherapy success

Immunodiagnosis: Unleashing the potential of personalized immunotherapy

Immunodiagnosis: Unleashing the potential of personalized immunotherapy

High tumor monocyte content linked to better outcomes for esophageal cancer patients

High tumor monocyte content linked to better outcomes for esophageal cancer patients

Immunotherapy significantly improves overall survival for advanced NSCLC patients

Immunotherapy significantly improves overall survival for advanced NSCLC patients

Two studies spotlight intestinal T cells that could be targeted to prevent resistance to ICB cancer therapy

Two studies spotlight intestinal T cells that could be targeted to prevent resistance to ICB cancer therapy

Study assesses the safety, efficacy of using immune checkpoint inhibitors in patients with advanced kidney cancer

Study assesses the safety, efficacy of using immune checkpoint inhibitors in patients with advanced kidney cancer

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

Multiple sclerosis: Immune cell invasion enabled by blood-brain barrier breakdown

Multiple sclerosis: Immune cell invasion enabled by blood-brain barrier breakdown

Researchers report the role of RNA-binding protein Msi 1 to maintain breast cancer stem cells

Researchers report the role of RNA-binding protein Msi 1 to maintain breast cancer stem cells

Study pinpoints how gut microbes boost the body's response to cancer immunotherapy

Study pinpoints how gut microbes boost the body's response to cancer immunotherapy

Spatial organization of immune cells predicts outcomes for patients with clear cell renal cell carcinoma

Spatial organization of immune cells predicts outcomes for patients with clear cell renal cell carcinoma

Checkpoint inhibitors may not be effective lymphoma treatment when CAR T fails

Checkpoint inhibitors may not be effective lymphoma treatment when CAR T fails

Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes

Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes

Diverse subset of T-cell clones plays a role in the antitumor effects of immune checkpoint inhibitors

Diverse subset of T-cell clones plays a role in the antitumor effects of immune checkpoint inhibitors

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.